Please login to the form below
Yescarta
This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
If approved, tafasitamab will go on to compete with existing cancer drugs including CAR-T therapies like Novartis’ Kymriah (tisagenlecleucel) and Gilead’s Yescarta (axicabtagene ciloleucel).
Latest news
-
Gilead owes BMS millions after losing Yescarta patent infringement trial
Gilead has been ordered to pay BMS $585m in damages, plus a 27.6% running royalty on all sales of Yescarta (axicabtagene ciloleucel). ... The efficacy data looks similar on paper to the two approved CAR-T therapies – Yescarta and Novartis’ Kymriah
-
Armed with new data, BMS plans filings for Celgene CAR-T liso-cel
third-to-market competitor to Novartis’ Kymriah(tisagenlecleucel) and Gilead Sciences Yescarta (axicabtagene ciloleucel). ... Meanwhile, in the same period Yescarta brought in $183m from its use in DLBCL and other B-cell lymphoma types.
-
Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
If approved (possibly in 2023) it would be a competitor to Novartis’ and Gilead/Kite’s CART-T therapies – Kymriah and Yescarta, respectively – which also target CD19 receptors.
-
Gilead promotes Andrew Dickinson to CFO, increased M&A expected
Gilead acquired the rights to Kite’s CAR-T therapy Yescarta (axicabtagene ciloleucel) for lymphoma in that deal – however, the drug continues to fall short of analyst expectations, bringing in $264m
-
SMC approves Yescarta and Keytruda, rejects Perjeta
The SMC has approved Yescarta for the treatment for adults patients with certain types of lymphoma as a second-line therapy through its Patient and Clinician Engagement (PACE) process. ... The regulatory authority said that Yescarta “could
More from news
Approximately 11 fully matching, plus 46 partially matching documents found.
Latest Intelligence
-
25 Women Leaders in UK Healthcare (part 2)
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
-
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
-
Cell and gene therapy
Cell and gene therapies are currently expensive to manufacture. We do not believe that recently marketed products, with US prices ranging from $373, 000 for Yescarta to $850, 000 for Luxturna,
-
Drug launches to watch in 2019
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Vice President
-
Competitive Salary Offered
-
Consultant
-
competitive salary
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
Subscribe to our email news alerts
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- NantKwest rockets on promising pancreatic cancer data
- FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC
- Genital herpes vaccine candidate heads for human studies
- Bayer bulks up in women’s health again with non-hormonal contraceptive deal
- Welcome to the Communique Awards - Communiqué Awards 2018
- How do companies prepare for reimbursement?
- Lucid Group adds more magic to the mix with four new hires
- Communiqué Awards 2020 is now open for entry
- Novo Nordisk gets MACE prevention claim for Ozempic in US
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
Latest intelligence
- How do companies prepare for reimbursement?
- Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
- Integrating electronic health records into clinical trials
- How organisations are working to realise the research potential of EHRs...
- Keeping up the fight against HIV and using the lessons to tackle other threats
- Danny Buckland interviews Gilead’s Mike Elliott...
Quick links
Infographics
